Analysts Set LifeMD, Inc. (NASDAQ:LFMD) PT at $9.14

Shares of LifeMD, Inc. (NASDAQ:LFMD) have been given a consensus recommendation of “Moderate Buy” by the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating and eight have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $9.1429.

A number of equities research analysts recently commented on the company. Weiss Ratings raised LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. BTIG Research reaffirmed a “buy” rating and set a $10.00 price objective on shares of LifeMD in a report on Monday, May 4th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of LifeMD in a research note on Tuesday, May 26th. Wall Street Zen downgraded shares of LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, Zacks Research lowered shares of LifeMD from a “hold” rating to a “strong sell” rating in a research report on Friday, July 17th.

Hedge Funds Weigh In On LifeMD

Hedge funds have recently modified their holdings of the company. Federated Hermes Inc. boosted its stake in shares of LifeMD by 278.1% in the 4th quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock worth $3,343,000 after buying an additional 721,018 shares during the last quarter. Prescott Group Capital Management L.L.C. bought a new position in shares of LifeMD in the fourth quarter valued at approximately $2,344,000. Arrowstreet Capital Limited Partnership increased its position in shares of LifeMD by 1,767.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company’s stock valued at $5,924,000 after acquiring an additional 411,651 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in LifeMD by 581.2% during the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock worth $5,619,000 after acquiring an additional 352,004 shares during the period. Finally, Whetstone Capital Advisors LLC lifted its holdings in LifeMD by 89.6% during the fourth quarter. Whetstone Capital Advisors LLC now owns 703,053 shares of the company’s stock worth $2,397,000 after acquiring an additional 332,269 shares during the period. Institutional investors own 35.52% of the company’s stock.

LifeMD Stock Performance

LFMD stock opened at $3.88 on Monday. The business has a 50-day simple moving average of $4.54 and a two-hundred day simple moving average of $3.99. The company has a market capitalization of $187.64 million, a P/E ratio of 77.62 and a beta of 1.99. LifeMD has a 52-week low of $2.56 and a 52-week high of $12.72.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.06). LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%.The company had revenue of $50.16 million during the quarter, compared to analysts’ expectations of $48.84 million. As a group, sell-side analysts forecast that LifeMD will post -0.37 earnings per share for the current fiscal year.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.